Drugs / BIRB 796 BS
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02211885 | Oct → Nov 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02209805 | Jan → Mar 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02214888 | May 2003 → Jan 2004 | rheumatoid arthritis | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT02209753 | Jun 2001 → Sep 2002 | psoriasis | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIRB 796 BS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02209753 ↗ |
| Known as | BIRB 796 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02211885 ↗ |
| Route | Oral | “BIRB 796 BS 5, 10, 20 and 30 mg Oral Tablets” NCT02209753 ↗ |